Annual Sales of Brilinta reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Brilinta Market Competitive Landscape The competitive landscape of the Brilinta market is characterized by a predominantly consolidated structure, with a few global pharmaceutical giants commanding significant market share through extensive R&D investments, strategic alliances, and robust manufacturing capabilities. Worldwide Brilinta Market 2026 Global Brilinta Market Size, Share & Industry Analysis, By Dosage Strength (90mg Tablets, 60mg Tablets), By Indication (Acute Coronary Syndrome, Coronary Artery Disease), and Regional Forecast 2026-2032. The Brilinta market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. The Brilinta Market Analysis market report covers financials, market share, SWOTs, and responses to Tariffs, while providing global, regional, and country-level forecasts supported by value chain, patent analysis, and a competitive matrix serving as a key resource for stakeholders and investors. Brilinta Market size was valued at USD 2.14 Bn in 2025, and the Brilinta Market revenue is expected to grow at a CAGR of 9% Chapter 3, the Brilinta competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Brilinta breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031. The Brilinta Market was valued at USD 1,506.2 million in 2024 and is projected to reach USD 2,329.1 million by 2032, growing at a CAGR of 5.6% during the forecast period. The Brilinta market was valued at $6.8 billion in 2025 and is projected to reach $11.2 billion by 2034, growing at 5.8% CAGR. Global analysis of antiplatelet therapy market trends. Brilinta Market Insights The global Brilinta market size was valued at USD 1.85 billion in 2025. The market is projected to grow from USD 1.98 billion in 2026 to USD 3.42 billion by 2034, exhibiting a CAGR of 7.1% during the forecast period. Brilinta, the trade name for ticagrelor, is an antiplatelet medication developed by AstraZeneca and primarily used to prevent cardiovascular events such … To focus on the key Brilinta Market manufacturers, defining, describing, and analyzing their sales volume, value, market share, market competition landscape, SWOT analysis, and development plans. To analyze the Brilinta Market with respect to individual growth trends, prospects, and their contribution to the total market. Sales of Brilinta slid 7% to $385 million in Q3 due to COVID-19 and a wholesaler inventory adjustment in China after the drug was found to be squaring off against local generics for a place in the … Annual Sales of Ticagrelor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. It's a blow to AZ, particularly after Brilinta had begun to gather speed. Stepped-up marketing and one new indication helped boost sales by 48% for the first half of this year. AstraZeneca's Parthenon program for Brilinta has been a hit-and-miss affair despite $3.7 billion in R&D costs. (AstraZeneca) With a series of late-stage trial readouts in the past few years … BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1 … BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Brilinta, a cardiometabolic drug once projected as a blockbuster but which underperformed expectations, is also losing U.S. patent protection soon (2). To illustrate the prominence of drugs on this list, last year's leader was Bristol Myers Squibb's Sprycel, with $1.45 billion in prior-year U.S. sales. Brilinta Market Overview The global Brilinta Market size is projected to grow from USD 2248.57 million in 2026 to USD 2440.69 million in 2027, reaching USD 4705.16 million by 2035, expanding at a CAGR of 8.55% during the forecast period. Compare prices and print coupons for Ticagrelor at major pharmacies. Find savings tips for this medication on GoodRx. Ticagrelor (Generic for Brilinta) Why does my medication look different? Product images are for illustrative purposes only. We can not guarantee a specific manufacturer when you place an order. The medication you receive may look different but the drug, strength, and ingredients are the same. The global Brilinta market size is expected to reach $ million by 2031, rising at a market growth of %CAGR during the forecast period (2025-2031). AstraZeneca's <AZN.L> heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, prompting the company to scrap a $3.5 billion-a-year (2.75 billion … Transfer your prescription for BRILINTA 90 MG TAB on Amazon Pharmacy. FREE SHIPPING for Prime members. Global Brilinta Market Size And Forecast The Global Brilinta Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027. And an FDA thumbs-up for Brilinta treatment beyond the one-year mark could actually foster more use in the drug's current eligible patient pool, Marc Ditmarsch, AstraZeneca's global lead for … Compare generic Brilinta (ticagrelor) 60 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for generic Brilinta (ticagrelor). Discounts up to 80% off the retail price. The Ticagrelor Market size reached USD 1.42 billion in 2026 and is expected to grow to USD 2.22 billion by 2035, registering a CAGR of 5.1%. With $6.72 billion in U.S. sales in 2024, the drug is the largest U.S. loss of exclusivity since AbbVie's megablockbuster Humira tumbled over the patent cliff in early 2023. Compare Brilinta prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. Results for blood thinning treatment boost prospects for AstraZeneca's sales targets AstraZeneca is one of the day's bigger risers in a falling market after a positive update on its Brilinta … AstraZeneca's heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, prompting the company to scrap a $3.5 billion-a-year sales target for the medicine by … Compare ticagrelor prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. The global market for Brilinta was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period. Key Takeaways Ticagrelor holds a substantial share of the antiplatelet market, with sales driven by efficacy and guideline endorsement. Patent expirations scheduled for 2026-2027 will reduce prices significantly. While current prices are stable, generics will exert downward pressure, especially in price-sensitive markets. Brilinta (ticagrelor), developed by AstraZeneca, is a P2Y12 platelet inhibitor approved for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or prior myocardial infarction (MI). It competes primarily with clopidogrel, prasugrel, and newer antiplatelet agents. The Brilinta market size, estimations, and forecasts are provided in terms of sales volume (k pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Brilinta market comprehensively. AstraZeneca Plc, the U.K.'s second-largest drugmaker, forecast that profit and sales would decline this year as its best-selling cholesterol medicine loses market exclusivity in the U.S. A Brilinta supplier is an individual or a company that provides Brilinta active pharmaceutical ingredient (API) or Brilinta finished formulations upon request. The Brilinta suppliers may include Brilinta API manufacturers, exporters, distributors and traders.
